A Study Protocol on the Overlooked Role of ABCB1Pharmacogenetics in Atorvastatin Therapy: A Systematic Review of Clinical, Pharmacokinetics, and Population Evidence
Keywords:
Genetic polymorphism, Atorvastatin, Pharmacokinetics, Personalized medicine, Adverse drug reactionsAbstract
Atorvastatin is widely used for dyslipidaemia and cardiovascular disease prevention, yet interindividual variability in efficacy and adverse effects, particularly statin-induced myopathy, limits its clinical use. Pharmacogenetic studies have largely focused on SLCO1B1 and CYP3A4/5; the role of ABCB1, which encodes P-glycoprotein, remains underexplored. This review aims to systematically evaluate the influence of ABCB1 polymorphisms on atorvastatin pharmacokinetics, efficacy, and safety outcomes. Following PRISMA guidelines, clinical studies involving adults on atorvastatin therapy will be identified from PubMed, Web of Science, and Scopus. Eligible studies must assess associations between common ABCB1 variants (e.g., C3435T, G2677T/A, and C1236T) and atorvastatin response outcomes. Data on study design, population, demographics, genotyping, and other key findings will be extracted. The risk of bias will be assessed using the Newcastle-Ottawa Scale for observational studies, and a meta-analysis will be performed. The review will clarify the contribution of ABCB1 polymorphisms to atorvastatin pharmacokinetics, lipid- lowering efficacy, and adverse events. It will also explore ethnic differences in allele frequencies and treatment response. By addressing this overlooked aspect of statin pharmacogenetics, the insights gained may support the integration of ABCB1 genotyping into clinical decision-making and enhance personalised cardiovascular therapy.
References
1. Akunne O, Adedapo ADA. Quality of statins prescription in patients admitted at a tertiary hospital in Southwestern Nigeria: Focus on cost containment. African J Biomed Res. 2018;21(3):251–5.
2. Sygitowicz G, Sitkiewicz D, Wrzosek K, Dłuźniewski M. The Impact of Atorvastatin Treatment on the Distribution of Low-Density Lipoprotein Subfractions and the Level of Vitamin D in Patients After Acute Myocardial Infarction: Preliminary Findings. Int J Mol Sci. 2024;25(20).
3. Balling M, Nordestgaard BG, Varbo A, Langsted A, Kamstrup PR AS. Small Dense Low-Density Lipoprotein Cholesterol and Ischemic Stroke. Ann Neurol. 2023;93(5):952–64.
4. Tian Y, Xu B, Guo S, Li Q, Zhao H, Zhao Y. Association of ABCB1 G2677T polymorphism with atorvastatin lipid efficacy and extended prognosis in patients with cerebral ischemic stroke. 2025;1–9.
5. Jiang Z, Wu Z, Liu R, Du Q, Fu X, Li M, et al. Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease. 2023;(February):1–15.
6. Abed W, Abujbara M, Batieha A, Ajlouni K. Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & genetics. Ann Med Surg [Internet]. 2022;74(November 2021):103304. Available from: https://doi.org/10.1016/j.amsu.2022.103304
7. Park JW, Kim JM, Lee HY, Noh J, Kim KA, Park JY. CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin. Pharmaceutics. 2022;14(7):1–11.
8. Kiander W, Sinokki A, Neuvonen M, Kidron H, Niemi M. Comparative uptake of statins by hepatic organic anion transporting polypeptides. Eur J Pharm Sci [Internet]. 2025;209(December 2024):107073. Available from: https://doi.org/10.1016/j.ejps.2025.107073
9. Zubiaur P, Benedicto MD, Villapalos-García G, Navares-Gómez M, Mejía-Abril G, Román M, et al. Slco1b1 phenotype and cyp3a5 polymorphism significantly affect atorvastatin bioavailability. J Pers Med. 2021;11(3):1–15.
10. Mykkänen AJH, Tarkiainen EK, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Lilius TO, et al. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP. Clin Pharmacol Ther. 2024;115(6):1428–40.
11. Vanwong N, Tipnoppanon S, Nakorn CN. Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid- Lowering Response to Statins in Thai Patients with Dyslipidemia Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to. 2022;7066.
12. Lalatović N, Ždralević M, Antunović T, Pantović S. Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin ‑ induced muscle side effects : a cross ‑ sectional study. Sci Rep [Internet]. 2023;1–9. Available from: https://doi.org/10.1038/s41598-023-44792-2
13. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev [Internet]. 2016;5(1):1–10. Available from: http://dx.doi.org/10.1186/s13643-016-0384-4
14. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu, R Currie M, Qureshi R, Mattis P, Lisy K MPF. Checklist for analytical cross sectional studies. Joanna Briggs Inst Rev Man [Internet]. 2017;1–7. Available from: http://joannabriggs.org/research/critical-appraisal-tools.
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Vol. 9, Chinese Journal of Evidence-Based Medicine. 2009. p. 8–11.
